GH Similar Chart Price Prediction
The price of GH is predicted to go up -1.91%, based on the high correlation periods with EPAC. The similarity of these two price pattern on the periods is 99.01%.
GH
EPAC
Down: -1.91%Similarity: 99.01%
GH Revenue Forecast
GH EPS Forecast
GH FAQs
What is bull’s view on GH?
What is bear's view on GH?
What is GH revenue forecast for next quarter？
What is GH eps forecast for next quarter？
GH VS S&P500
Guardant is a leader in liquid biopsy and has been a step ahead of the competition, which could eventually enable it to secure a lasting first-mover advantage with its Shield test.
Guardant's pipeline targets areas with a reasonably clear path to reimbursement and reasonably good barriers to entry, including MRD surveillance and its blood-based CRC screening test.
Market estimates for Guardant could prove conservative if liquid biopsy adoption occurs faster than anticipated.
GH Analyst's Forecast
Luke Sergott
Barclays
Buy
2025-01-23
Price Target
$60
Upside
+23.46%
Barclays initiated coverage of Guardant Health with an Overweight rating and $60 price target. The firm started the liquid biopsy space with Overweight ratings on three names. The technology is "breaking out" with broader adoption across key markets, the analyst tells investors in a research note. Barclays expects volumes to continue to ramp as companies publish data, expand menus across indications and markets, and payers increase coverage across lives as this technology continues to show its utility. "It is too early to pick a winner given how early we are in adoption, so in the meantime we believe that a rising tide will lift all boats," contends the firm. Barclays sees a "very long runway" from the underpenetrated markets as coverage unlocks selling prices and additional indications unlock more addressable markets.
Eve Burstein
Bernstein
Buy
2024-10-30
Price Target
$40 → $35
Upside
+51.71%
